AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Exclusion Criteria

• •1. Previous (within 3 years) or concurrent other malignant tumors, excluding those that have been cured.
• •2. Participating in other interventional study within 4 weeks prior to the first study drug administration.
• •3. Palliative local treatment for non-target lesions within 2 weeks prior to the first administration; received non-specific immunomodulatory therapy within 2 weeks prior to the first administration.
• •4. Current presence of uncontrolled combined disease.
• •5. Active clinical infections.
• •6. History of severe bleeding tendency or coagulation dysfunction.
• •7. Subjects with known active tuberculosis (TB); suspected active TB should be excluded by clinical examination, known active syphilis infection.
• •8. Received a live vaccine within 30 days prior to the study, or plan to receive a live vaccine during the study.
• •9. Current presence of significant radiographic or clinical manifestations of GI obstruction.
• •10. Toxicities of prior anticancer therapy have not resolved to ≤ Grade 1 (NCI-CTCAE version 5.0).
• •11. Pregnant or lactating women.
• •12. Any condition considered by the investigator to be inappropriate for enrollment.
• •13. Local or systemic disease caused by non-malignancy, or disease or symptom secondary to tumor, that can lead to higher medical risk and/or uncertainty in survival.